David Shamblaw

1.2k total citations
7 papers, 379 citations indexed

About

David Shamblaw is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, David Shamblaw has authored 7 papers receiving a total of 379 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Infectious Diseases, 6 papers in Virology and 3 papers in Emergency Medicine. Recurrent topics in David Shamblaw's work include HIV/AIDS drug development and treatment (7 papers), HIV Research and Treatment (6 papers) and HIV/AIDS Research and Interventions (3 papers). David Shamblaw is often cited by papers focused on HIV/AIDS drug development and treatment (7 papers), HIV Research and Treatment (6 papers) and HIV/AIDS Research and Interventions (3 papers). David Shamblaw collaborates with scholars based in United States, United Kingdom and Germany. David Shamblaw's co-authors include Peter Ruane, Hui C. Liu, Jason Flamm, Scott McCallister, Edwin DeJesus, Moupali Das, Ramin Ebrahimi, Cheryl McDonald, Richard Elion and Brian P. Kearney and has published in prestigious journals such as AIDS, JAIDS Journal of Acquired Immune Deficiency Syndromes and Journal of the International AIDS Society.

In The Last Decade

David Shamblaw

7 papers receiving 376 citations

Peers

David Shamblaw
Amanda Clarke United Kingdom
Awny Farajallah United States
David Piontkowsky United States
Elisabetta Chiesa Italy
Antonio Antela Spain
Naomi Givens United Kingdom
Ya-Pei Liu United States
Gianmaria Baldin Italy
Rima Acosta United States
Anita Scribner United States
Amanda Clarke United Kingdom
David Shamblaw
Citations per year, relative to David Shamblaw David Shamblaw (= 1×) peers Amanda Clarke

Countries citing papers authored by David Shamblaw

Since Specialization
Citations

This map shows the geographic impact of David Shamblaw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Shamblaw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Shamblaw more than expected).

Fields of papers citing papers by David Shamblaw

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Shamblaw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Shamblaw. The network helps show where David Shamblaw may publish in the future.

Co-authorship network of co-authors of David Shamblaw

This figure shows the co-authorship network connecting the top 25 collaborators of David Shamblaw. A scholar is included among the top collaborators of David Shamblaw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Shamblaw. David Shamblaw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Huhn, Gregory, David Shamblaw, Jean‐Guy Baril, et al.. (2019). Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate. Open Forum Infectious Diseases. 7(1). ofz472–ofz472. 33 indexed citations
2.
Mills, Anthony, Gordon Crofoot, Cheryl McDonald, et al.. (2015). Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 69(4). 439–445. 121 indexed citations
3.
Tebas, Pablo, Martin Fisher, Brian Gazzard, et al.. (2013). Efficacy of switching to rilpivirine/emtricitabine/tenofovir DF from boosted PI in HIV-1 virologically suppressed patients with or without the K103N. Journal of the International AIDS Society. 16(Suppl 1). 2 indexed citations
4.
5.
Fisher, Martin, Frank J. Palella, Pablo Tebas, et al.. (2012). SPIRIT: switching to emtricitabine/rilpivirine/tenofovir DF single‐tablet regimen from boosted protease inhibitor maintains HIV suppression at week 48. Journal of the International AIDS Society. 15(S4). 1–1. 11 indexed citations
6.
7.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Amanda Clarke Breakdown of academic impact, for papers by Awny Farajallah Breakdown of academic impact, for papers by David Piontkowsky Breakdown of academic impact, for papers by Elisabetta Chiesa Breakdown of academic impact, for papers by Antonio Antela Breakdown of academic impact, for papers by Naomi Givens Breakdown of academic impact, for papers by Ya-Pei Liu Breakdown of academic impact, for papers by Gianmaria Baldin Breakdown of academic impact, for papers by Rima Acosta Breakdown of academic impact, for papers by Anita Scribner
Rankless by CCL
2026